Home > Insider Trading > Filing (0000919574-24-000757)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
876343	Lineage Cell Therapeutics Inc.	LCTX	Biological Products, (No Disgnostic Substances) (2836)	943127919

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278386	Broadwood Partners, L.p.	C/O Broadwood Capital Inc. 142 West 57Th Street, 11Th Floor New York NY 10019	Yes	No	Yes	No
1278387	Broadwood Capital Inc	142 West 57Th Street, 11Th Floor New York NY 10019	No	No	Yes	No
1278388	C Neal Bradsher	C/O Broadwood Capital Inc. 142 West 57Th Street, 11Th Floor New York NY 10019	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2024-02-06	6,730,770	$1.04	41,666,255	No	4	P	Direct
Common Shares	Acquisiton	2024-02-06	0	$0.00	41,666,255	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	87,628	Direct

Footnotes

The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share.
These securities are owned by Neal C. Bradsher in his personal capacity.